Two recent studies evaluated the effects of asthma through addressing the costs and adherence to medications as well as the accessibility to certain resources for patients.
Two recent studies evaluated the effects of asthma through addressing the costs and adherence to medications as well as the accessibility to certain resources for patients.
One study assessed the patient adherence in Australia, specifically looking at the cost-related under-use of asthma medicines among adults and children. The study involved a cross-sectional population-based online survey of adults with asthma and parents of children between the ages of 5 and 17 with asthma.
The results consisted of completed surveys from 792 adults with asthma and 609 parents of children with asthma. Of the adults, 419 (52.9%) reported delaying or skipping refills/doses or taking fewer puffs in the last 12 months because of the cost, while 243 (30.7) reported foregoing basic needs in the last 12 months to pay for asthma medicines.
For the parents of children with asthma, 209 (34.3%) reported delaying or skipping doses or taking fewer puffs in the last 12 months due to the cost, and 269 (44.2%) reported foregoing basic needs in the last 12 months for asthma treatment.
Additionally, the results revealed that cost-related medicine under-use was reported lower among:
“Health professionals should be encouraged to ask patients if they have concerns about their asthma medicines including about cost; to optimize cost-effectiveness by checking inhaler technique and avoiding over-treatment; and to consider offering options with a lower overall out-of-pocket cost,” the authors concluded.
Another study investigated if an English-only patient portal of the electronic health record would benefit patients who have limited educational opportunities, resources, and access to information technology.
The study included adults with uncontrolled asthma who lived in low-income urban neighborhoods. Each patient received portal training (PT) and half were randomized to home visits (HV) by community health workers. The training included 7 tasks, such as reviewing an upcoming appointment and requesting a refill. The patients were followed for 1 year.
The results revealed fewer than 60% of patients used the portal independently—the frequeny of portal use was associated with younger age, higher reported household income, and education beyond high school. Portal use was also less likely in patients with diabetes, hypertension, or hospitalizations for asthma, but it was not linked with gender, race, ethnicity, or Spanish as a primary language.
The most frequent usage of the portal was for reading messages and getting lab results, while the least frequent usage was sending messages and making appointments.
“Patients with the most uncontrolled asthma and other medical comorbidities were least likely to use the portal,” the authors concluded. “The patient portal needs revision to accommodate patients with the highest asthma morbidity and healthcare needs.”
References
1. Reddel HK, Laba T, Jan S, et al. Effects of out-of-pocket costs on patient adherence with asthma medicines. Presented at the American Thoracic Society 2018 International Conference. May 20, 2018; San Diego, California. Abstract A1083.
2. Apter AJ, Bryant-Stephens T, Perez L, et al. Electronic health record patient portal access for low income and minority adults with uncontrolled ashtma. Presented at the American Thoracic Society 2018 International Conference. May 20, 2018; San Diego, California. Abstract A1074.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More